Последняя версия ADB AppControl Mobile
Загружая и используя приложение "ADB AppControl Mobile" вы соглашаетсь с Условиями Использования и Политикой Конфиденциальности.
Удаляйте и отключайте (замораживайте) приложения с помощью ADB. Управляйте приложениями в рабочем профиле или втором пространстве. Устанавливайте файлы apk, apks и xapk.
Выполняйте команды ADB на вашем Android-устройстве из удобной встроенной консоли с подсветкой синтаксиса. MIRD-226
Приложения на вашем устройстве могут обновляться в фоновом режиме, даже если вы отключили автоматические обновления. ADB AppControl уведомит вас об установленных и обновленных приложениях. In 2018, a new radiopharmaceutical, MIRD-226, was developed
Подключайтесь к другим устройствам Android в вашей локальной сети за считанные секунды и получите все возможности ADB. MIRD-226 works by binding to somatostatin receptors on
In 2018, a new radiopharmaceutical, MIRD-226, was developed to overcome these limitations. MIRD-226 is labeled with Lutetium-177 (Lu-177), a radioactive isotope with a longer half-life than Indium-111 (In-111). This allows for more efficient and prolonged treatment of NETs.
MIRD-226 works by binding to somatostatin receptors on the surface of NET cells. Once bound, the radiopharmaceutical is internalized by the cell, where the Lu-177 isotope emits beta particles that damage the tumor cells. This results in the death of the tumor cells, while minimizing damage to surrounding healthy tissues.
The development of MIRD-226 dates back to the early 2000s, when researchers began exploring the use of radiolabeled somatostatin analogues for the treatment of NETs. The first generation of these radiopharmaceuticals, such as In-111-DOTATOC, showed promising results in diagnosing and treating NETs. However, they had limitations, including a short half-life and limited availability.
The field of nuclear medicine has witnessed significant advancements over the years, with various radiopharmaceuticals being developed to diagnose and treat a range of diseases. One such notable development is the MIRD-226, a radiopharmaceutical that has been gaining attention in recent years due to its potential applications in nuclear medicine.
